Physician profile
James N Moore
NPI 1134171531
$3,897.65
in general payments reported to CMS, 2019-2025
27 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $588 · 2021: $1,171 · 2022: $698 · 2023: $419 · 2024: $293 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,128.02 | 2021-2025 | |
| Novo Nordisk INC | $501.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $284.65 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $270.42 | 2019-2025 | Breztri, Farxiga |
| Amarin Pharma, INC. | $251.28 | 2019-2021 | |
| Pfizer INC. | $230.60 | 2019-2021 | |
| Abbott Laboratories | $229.75 | 2019-2022 | |
| Amgen INC. | $210.85 | 2019-2023 | Otezla, Repatha |
| Allergan, INC. | $139.67 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $110.70 | 2021 | |
| Exact Sciences Corporation | $88.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $85.00 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $79.99 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $41.38 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $36.18 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $30.93 | 2019-2020 | |
| Aytu Biopharma, INC. | $22.59 | 2019 | |
| Valinor Pharma, LLC | $19.43 | 2024 | Movantik |
| Pacira Pharmaceuticals Incorporated | $18.58 | 2024 | Iovera, Zilretta |
| Takeda Pharmaceuticals U.S.A., INC. | $16.38 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.10 | 2020 | |
| Boston Scientific Corporation | $15.33 | 2019 | |
| Depuy Synthes Sales INC. | $14.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2023 | Seglentis, Livalo |
| Apria Healthcare LLC | $13.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.